NGL Fine-Chem Limited (NSE:NGLFINE)

India · Delayed Price · Currency is INR

2,899.60

-35.20 (-1.20%)

Nov 11, 2026, 1:12 PM IST

Market Cap	17.90B +96.4%
Revenue (ttm)	5.75B +40.7%
Net Income	639.05M +204.9%
EPS	103.44 +205.8%
Shares Out	n/a
PE Ratio	28.03
Forward PE	n/a
Dividend	1.75 (0.06%)
Ex-Dividend Date	Aug 18, 2026

Volume	4,118
Open	2,990.60
Previous Close	2,934.80
Day's Range	2,890.00 - 2,990.60
52-Week Range	1,271.00 - 3,602.00
Beta	0.90
Analysts	n/a
Price Target	n/a
Est. Earnings	Feb 4, 2027

About NGL Fine-Chem

NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol, homidium chloride, imidocarb dipropionate, isometamidium chlroide HCl, lotilaner, marbofloxac... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1981

Employees 498

Stock Exchange National Stock Exchange of India

Ticker Symbol NGLFINE

Full Company Profile

Financial Performance

In fiscal year 2026, NGL Fine-Chem's revenue was 5.01 billion, an increase of 36.03% compared to the previous year's 3.68 billion. Earnings were 481.27 million, an increase of 127.83%.

Financial Statements